v3.26.1
Segment Information
12 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information Segment Information
The Company manages its operations on a consolidated basis as a single operating and reportable segment with a focus on developing and commercializing novel oncolytic immunotherapies in order to treat cancer. The Company defines its segments on the basis of the way in which internally reported financial information is regularly reviewed to analyze financial performance and make operating decisions. The Company’s Chief Operating Decision Maker ("CODM") is Sushil Patel, the Chief Executive Officer. The CODM reviews consolidated operating results, and uses the Company's consolidated net income (loss), in order to monitor actual results as compared to the budget, and to determine how best to allocate the Company's operating and capital resources, specifically as it relates to the Company's development programs.
The following table presents selected financial information with respect to the Company's single operating segment, including significant segment expenses by program, for the years ended March 31, 2026 and 2025:
Year Ended March 31,
20262025
Operating expenses:(Amounts in thousands)
Direct research and development expenses by program:
       RP1 program costs by study:
  IGNYTE9,541 14,620 
  ARTACUS5,884 6,934 
  CERPASS4,559 7,276 
  IGNYTE-321,264 7,183 
  Other RP1 study costs18,523 10,863 
RP225,953 12,043 
RP32,674 4,948 
Unallocated research and development expenses1:
132,786 125,580 
Selling, general and administrative98,735 72,180 
Total operating expenses319,919 261,627 
Loss from operations(319,919)(261,627)
Other income (expense), net5,428 $14,798 
Loss before income taxes$(314,491)$(246,829)
Income tax provision(551)468 
Net loss(313,940)(247,297)
1 Includes personnel-related costs and other costs